论文部分内容阅读
目的:观察促红细胞生成素(ESPO)注射剂治疗早产儿贫血的效果,探讨治疗中补充铁剂的临床意义。方法:将51例应用ESPO治疗的贫血早产儿随机分为联合用药组(31例)和对照组(20例),两组均予ESPO200U/kg皮下注射,每周2次;联合组在此基础上给予琥珀酸亚铁20mg/kg·d～25mg/kg·d。于治疗前后测血清铁、血清铁蛋白、血常规、肝肾功能。结果:8周后两组间外周血血红蛋白、红细胞、红细胞压积、治疗有效率、血清铁、血清铁蛋白出现显著性差异(P<0.01),联合组上述指标均显著高于对照组,且无明显副作用。结论:ESPO和琥珀酸亚铁联合应用治疗早产儿贫血能提高治疗效果,避免治疗中血清铁、血清铁蛋白的下降,联合应用安全有效。
Objective: To observe the effect of injection of erythropoietin (ESPO) on anemia in premature infants and to explore the clinical significance of iron supplementation in the treatment. Methods: Fifty-one preterm infants with anemia treated with ESPO were randomly divided into combined treatment group (n = 31) and control group (n = 20). Both groups were injected subcutaneously with ESPO 200U / kg twice a week. Given ferrous succinate 20mg / kg · d ~ 25mg / kg · d. Before and after treatment serum iron, serum ferritin, blood, liver and kidney function. Results: After 8 weeks, there were significant differences in hemoglobin, erythrocyte, hematocrit, therapeutic efficiency, serum iron and serum ferritin between the two groups (P <0.01). The above indexes in the combined group were significantly higher than those in the control group No obvious side effects. Conclusion: The combination of ESPO and ferrous succinate for the treatment of anemia in premature infants can improve the therapeutic effect and avoid the decrease of serum iron and serum ferritin during the treatment. The combination of ESPO and ferrous succinate is safe and effective.